Genspect UK Briefing: Puberty Blockers, Detransition and the NHS Trial
This comprehensive briefing from Genspect UK presents the evidence on puberty blocker risks through research findings and detransitioner testimonies, advocating for evidence-based approaches to gender distress.
The briefing includes:
- Debunking of common myths about puberty blockers using evidence from the Cass Review
- Personal testimonies from detransitioners who have experienced puberty blockers
- Case studies highlighting the impact on sexual development and puberty anxiety
- Clear policy recommendations for a safer approach to gender distress
Key Findings from the Briefing
Debunked Myths
The briefing exposes seven common myths about puberty blockers, including claims that they are fully reversible, improve mental health or prevent suicide – none of which is supported by the evidence.
Personal Experiences
Detransitioners share their lived experiences with puberty blockers, including significant physical side effects and the impact on psychological development during adolescence.
Policy Recommendations
The briefing calls for a suspension of the NHS puberty blocker trial until better data is available, and advocates for a focus on less invasive psychotherapeutic approaches.
Featured Quote from a Detransitioner
“I think it’s a human rights violation to take that from a child because, like I said, I had no sexual experience before I went on blockers at 16.”
Jet, a detransitioned lesbian woman who shares her story in the briefing